Connecticut-based Astrocyte Pharmaceuticals Inc. closed a USD 9.5 million Series B financing round led by DeepWork Capital, ...
XYone Therapeutics, a Canton, Massachusetts-based clinical-stage biotechnology company, dosed the first patient in a Phase 1b/2 trial of XYA02 (AT2021), its... The FDA launched a nationwide ...
CMS finalized the mandatory GLOBE model, linking Medicare Part B rebates to international drug prices starting in 2027. See ...
Foghorn Therapeutics is cutting about 40% of its workforce after ending FHD-909 and other SMARCA2 programs with Lilly. Read ...
Atara Biotherapeutics resubmits tabelecleucel BLA to FDA for EBV+ post-transplant lymphoproliferative disease. Latest updates ...
Progentos begins Phase I/II human trial of oral PRO-1562 for multiple sclerosis remyelination. First-in-human study ...
Regeneron and Sanofi expand antibody alliance with $1B upfront and $7B in milestones for IL-4/IL-13 pathway treatments. Learn ...
AbbVie's amylin analog ABBV-295 achieves every-other-week dosing with significant weight loss in Phase I obesity trial. Full ...
Varda Space Industries secures $251M Series D funding to scale space-based pharmaceutical manufacturing. Learn how orbital ...
NRx Pharmaceuticals wins $11.2M DARPA funding to test NRX-101 combined with robotic TMS for treatment-resistant depression.
Eli Lilly's Ebglyss meets primary endpoints in Phase IIIb ADtouch trial for moderate-to-severe hand and foot atopic dermatitis. Label expansion expected.
CAS and Novartis collaborate on AI-ready reaction informatics for drug discovery. Access 160M+ curated reactions. Learn how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results